Actively Recruiting
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-04-07
60
Participants Needed
45
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
CONDITIONS
Official Title
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 80 years
- Documented diagnosis of acromegaly with a GH-secreting pituitary adenoma confirmed by MRI or pathology
- Receiving maximally tolerated long-acting somatostatin analogs (octreotide or lanreotide LAR) once monthly for at least 6 months prior to screening
- Partial responder to SSA therapy with more than 20% reduction in IGF-1 during treatment
- Serum IGF-1 levels between 1.3 and 5 times the upper limit of normal, confirmed by two tests at least 7 days apart during screening
You will not qualify if you...
- Pituitary surgery within 6 months before study start or planned during the study
- Worsening pituitary adenoma as judged by recent MRI or CT scan
- Pituitary adenoma causing optic chiasm compression
- Symptomatic hyperprolactinemia requiring dopamine agonist treatment
- Untreated or unstable hypothyroidism or hypocortisolism
- Active significant cardiac disease or recent unstable angina, stroke, or heart attack within 3 months
- Uncontrolled type 2 diabetes with HbA1c over 10%
- Active cancer within 2 years except certain skin cancers
- Recent fractionated radiotherapy or second pituitary surgery within last 3-5 years or planned during study
- Use of pegvisomant within 8 weeks or dopamine agonists within 4 weeks prior to screening
- Use of pasireotide LAR within 4 months prior to screening
- Significant kidney or liver disease or abnormal lab values as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 45 locations
1
Research Site
Los Angeles, California, United States, 90048
Actively Recruiting
2
Research Site
Los Angeles, California, United States, 90095
Actively Recruiting
3
Research Site
Torrance, California, United States, 90502
Actively Recruiting
4
Research Site
Aurora, Colorado, United States, 80045
Withdrawn
5
Research Site
Boston, Massachusetts, United States, 02114
Actively Recruiting
6
Research Site
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
7
Research Site
Las Vegas, Nevada, United States, 89148
Actively Recruiting
8
Research Site
New York, New York, United States, 10032
Actively Recruiting
9
Research Site
Portland, Oregon, United States, 97239
Actively Recruiting
10
Research Site
CABA, Argentina, C1012AAR
Actively Recruiting
11
Research Site
Ciudad de Buenos Aires, Argentina, C1180AAD
Actively Recruiting
12
Research Site
Ciudad de Buenos Aires, Argentina, C1199
Actively Recruiting
13
Research Site
Ciudad de Buenos Aires, Argentina, C1405DCS
Actively Recruiting
14
Research Site
Curitiba, Brazil, 80030-110
Actively Recruiting
15
Research Site
Ribeirão Preto, Brazil, 14049-901
Actively Recruiting
16
Research Site
Rio de Janeiro, Brazil, 20231-092
Actively Recruiting
17
Research Site
São Paulo, Brazil, 01420-000
Actively Recruiting
18
Research Site
Beijing, China, 100730
Not Yet Recruiting
19
Research Site
Guangzhou, China, 510120
Not Yet Recruiting
20
Research Site
Kunming, China, 650032
Not Yet Recruiting
21
Research Site
Shanghai, China, 201107
Not Yet Recruiting
22
Research Site
Copenhagen, Denmark, 2100
Actively Recruiting
23
Research Site
Odense, Denmark, 5464
Actively Recruiting
24
Research Site
Budapest, Hungary, 1083
Actively Recruiting
25
Research Site
Budapest, Hungary, 1134
Actively Recruiting
26
Research Site
Pécs, Hungary, 7624
Actively Recruiting
27
Research Site
Szeged, Hungary, 6725
Actively Recruiting
28
Research Site
Cona, Italy, 44124
Actively Recruiting
29
Research Site
Genoa, Italy, 16132
Actively Recruiting
30
Research Site
Messina, Italy, 98125
Actively Recruiting
31
Research Site
Milan, Italy, 20132
Not Yet Recruiting
32
Research Site
Naples, Italy, 80131
Not Yet Recruiting
33
Research Site
Pisa, Italy, 56126
Actively Recruiting
34
Research Site
Roma, Italy, 00168
Actively Recruiting
35
Research Site
Kaunas, Lithuania, LT50009
Actively Recruiting
36
Research Site
Vilnius, Lithuania, 09112
Actively Recruiting
37
Research Site
Leiden, Netherlands, 2333 ZA
Not Yet Recruiting
38
Research Site
Rotterdam, Netherlands, 3015 CE
Actively Recruiting
39
Research Site
Bydgoszcz, Poland, 85-605
Withdrawn
40
Research Site
Gliwice, Poland, 44-102
Not Yet Recruiting
41
Research Site
Krakow, Poland, 31-501
Not Yet Recruiting
42
Research Site
Warsaw, Poland, 03-242
Actively Recruiting
43
Research Site
Wroclaw, Poland, 50-367
Actively Recruiting
44
Research Site
Bucharest, Romania, 011863
Actively Recruiting
45
Research Site
Cluj-Napoca, Romania, 400006
Not Yet Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here